ENOV
Enovis CorporationNYSEIndustrialsAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.86
P/S
0.58
EV/EBITDA
-3.20
DCF Value
$-115.58
FCF Yield
1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.8%
Operating Margin
-52.6%
Net Margin
-52.7%
ROE
-54.4%
ROA
-63.0%
ROIC
-35.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $575.8M | $-520.6M | $-9.17 |
| FY 2025 | $2.25B | $-1.18B | $-20.86 |
| Q3 2025 | $548.9M | $-571.1M | $-10.06 |
| Q2 2025 | $564.5M | $-36.7M | $-0.64 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Industrials
Industry
—
Country
US
Exchange
NYSE
Beta
1.59
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.